Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nilotinib - Georgetown University/ KeifeRx

Next Previous
Drug Profile

Nilotinib - Georgetown University/ KeifeRx

Alternative Names: KFRX-01; Nilotinib BE

Latest Information Update: 28 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgetown University
  • Class Anilides; Aniline compounds; Antineoplastics; Benzamides; Fluorinated hydrocarbons; Imidazoles; Ketones; Pyridines; Pyrimidines; Small molecules; Toluenes
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Discoidin domain receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Lewy body disease; Parkinson's disease
  • No development reported Huntington's disease

Most Recent Events

  • 28 Feb 2023 No recent reports of development identified for phase-I development in Huntington's-disease(In the elderly, In adults) in USA (PO)
  • 09 Dec 2021 Georgetown University completes a phase II trial in Parkinson's disease (In the elderly, In adults) in USA (PO) (NCT02954978)
  • 08 Dec 2021 KeifeRx plans a phase III NILEAD trial for Alzheimer's disease (Early-stage disease) (PO, Capsule) in early 2022 (NCT05143528)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top